Search research articles
Contact Us
Filters
Showing results (791-800 of 839) with videos related to
Page
of 84
Sort By:
European Urology
|
April 1, 2019
Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer
William S Chen, Rahul Aggarwal, Li Zhang, et al.
Cancer Research
|
June 8, 2023
The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
Arian Lundberg, Meng Zhang, Rahul Aggarwal, et al.
European Urology Oncology
|
July 19, 2025
Radiotherapy- Versus Surgery-based Treatment Strategy in High-risk Prostate Cancer
Soumyajit Roy, Yilun Sun, James A Eastham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 10, 2018
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study
Rahul Aggarwal, Jiaoti Huang, Joshi J Alumkal, et al.
Cancer Letters
|
November 7, 2022
UGT2B28 accelerates prostate cancer progression through stabilization of the endocytic adaptor protein HIP1 regulating AR and EGFR pathways
Louis Lacombe, Hélène Hovington, Hervé Brisson, et al.
The Journal of Urology
|
September 2, 2015
Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort
Lisa F Newcomb, Ian M Thompson, Hilary D Boyer, et al.
Genome Medicine
|
February 20, 2019
BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma
Raunak Shrestha, Noushin Nabavi, Yen-Yi Lin, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 13, 2009
Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors
Martin E Swarbrick, Paul J Beswick, Robert J Gleave, et al.
NPJ Precision Oncology
|
July 7, 2025
Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancer
Anbarasu Kumaraswamy, Ya-Mei Hu, Joel A Yates, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 20, 2020
Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance
Joshi J Alumkal, Duanchen Sun, Eric Lu, et al.
Page
of 84
Search research articles
Search
Showing results (791-800 of 839) with videos related to
Sort By:
Page
of 84
European Urology
|
April 1, 2019
Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer
William S Chen, Rahul Aggarwal, Li Zhang, et al.
Cancer Research
|
June 8, 2023
The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
Arian Lundberg, Meng Zhang, Rahul Aggarwal, et al.
European Urology Oncology
|
July 19, 2025
Radiotherapy- Versus Surgery-based Treatment Strategy in High-risk Prostate Cancer
Soumyajit Roy, Yilun Sun, James A Eastham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 10, 2018
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study
Rahul Aggarwal, Jiaoti Huang, Joshi J Alumkal, et al.
Cancer Letters
|
November 7, 2022
UGT2B28 accelerates prostate cancer progression through stabilization of the endocytic adaptor protein HIP1 regulating AR and EGFR pathways
Louis Lacombe, Hélène Hovington, Hervé Brisson, et al.
The Journal of Urology
|
September 2, 2015
Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort
Lisa F Newcomb, Ian M Thompson, Hilary D Boyer, et al.
Genome Medicine
|
February 20, 2019
BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma
Raunak Shrestha, Noushin Nabavi, Yen-Yi Lin, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 13, 2009
Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors
Martin E Swarbrick, Paul J Beswick, Robert J Gleave, et al.
NPJ Precision Oncology
|
July 7, 2025
Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancer
Anbarasu Kumaraswamy, Ya-Mei Hu, Joel A Yates, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 20, 2020
Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance
Joshi J Alumkal, Duanchen Sun, Eric Lu, et al.
Page
of 84